Reversible encephalopathy caused by valproic acid in an adolescent with idiopathic generalised epilepsy;Encefalopatía reversible por ácido valproico en un adolescente con epilepsia generalizada idiopática

Revista de Neurologia

Volumn 55, Issue 11, 2012, Pages 663-668

  Raspall Chaure, Miquel ^a   Lainez, Elena ^a   Toledo, Manuel ^a   Salas Puig, Javier ^a   Macaya Ruiz, Alfons ^a   Roig Quilis, Manuel ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Aggravation; Encephalopathy; Hyperammonemia; Idiopathic generalised epilepsy; Toxicity; Valproic acid

Indexed keywords

VALPROIC ACID;

ARTICLE; BRAIN DISEASE; CASE REPORT; DISEASE CONTROL; DISEASE EXACERBATION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; GENERALIZED EPILEPSY; HUMAN; IDIOPATHIC DISEASE; MENTAL HEALTH; MILD COGNITIVE IMPAIRMENT;

EID: 84870705982     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5511.2012374     Document Type: Article

References (18)

1. Loring DW, Meador KJ. Cognitive side efects of antiepileptic drugs in children. Neurology 2004; 62: 872-877.
2. Gayatri NA, Livingston JH. Aggravation of epilepsy by anti-epileptic drugs. Dev Med Child Neurol 2006; 48: 394-398.
3. Gerstner T, Buesing D, Longin E, Bendl C, Wenzel D, Scheid B, et al. Valproic acid induced encephalopathy: 19 new cases in Germany from 1994 to 2003 -a side efect associated to VPA-therapy not only in young children. Seizure 2006; 15: 443-448.
4. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. Te SANAD study of efectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1016-1026.
5. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, Van Emde BW, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classifcation and Terminology, 2005-2009. Epilepsia 2010; 51: 676-685.
6. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efcacy and efectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094-1120.
7. Calleja S, Salas-Puig J, Ribacoba R, Lahoz CH. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate. Seizure 2001; 10: 424-427.
8. Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol 2005; 4: 239-248.
9. Dealberto MJ. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. Int Clin Psychopharmacol 2007; 22: 330-337.
10. Toribio-Díaz ME, Morera-Guitart J, Palao-Duarte S. Parkinsonismo y deterioro cognitivo reversibles tras tratamiento con ácido valproico. Rev Neurol 2008; 47: 390-391.
11. Lerman-Sagie T, Watemberg N, Kramer U, Shahar E, Lerman P. Absence seizures aggravated by valproic acid. Epilepsia 2001; 42: 941-943.
12. Shorvon SD, Perucca E, Engel J. Treatment of epilepsy. Oxford: Blackwell Publishing; 2009.
13. Jiménez-Parrilla F, Pérez-Sánchez A, Núñez-Solís JM, Madruga-Garrido M, Losada-Martínez A. Encefalopatía hiperamoniémica inducida por ácido valproico en período neonatal. Rev Neurol 2009; 48: 613-614.
14. Bryant AE, III, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996; 46: 465-469.
15. Gómez-Ibáñez A, Urrestarazu-Bolumburu E, Viteri-Torres C. Hyperammonemic encephalopathy related to valproate, phenobarbital, and topiramate synergism. Epilepsy Behav 2011; 21: 480-482.
16. Hamer HM, Knake S, Schomburg U, Rosenow F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000; 54: 230-232.
17. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs -best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Terapeutic Strategies. Epilepsia 2008; 49: 1239-1276.
18. Vaquerizo J, Gómez MH, González IE, Cardesa JJ. Reversible neuropsychological deterioration associated with valproate. Rev Neurol 1995; 23: 148-150.